Agios Pharm

Agios Pharm

Yahoo Finance • 4 days ago

Here's Why Shares in Novo Nordisk Rival, Agios Pharmaceutical, Soared This Week

Key Points Agios stock surged after FDA granted priority review for mitapivat in sickle cell disease. Mitapivat showed mixed Phase 3 results, and competition is coming from Novo Nordisk.10 stocks we like better than Agios Pharmaceuticals... Full story

Yahoo Finance • 7 days ago

FDA Accepts Agios' SNDA For Mitapivat In Sickle Cell Disease With Nov '26 PDUFA Date; Stock Up

(RTTNews) - Agios Pharmaceuticals Inc. (AGIO), a commercial-stage biopharmaceutical company, on Tuesday announced that the U.S. Food and Drug Administration (FDA) has accepted under a priority review the supplemental new drug application (... Full story

Yahoo Finance • last month

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease

Mitapivat demonstrated statistically significant improvement in hemoglobin response compared with placebo, with rapid onset and durable effects New analyses showed patients in mitapivat arm had clinically meaningful reduction in transfusio... Full story

Yahoo Finance • last month

Agios Enters Global License Agreement For Cevidoplenib

(RTTNews) - Agios Pharmaceuticals, Inc. (AGIO), a biopharmaceutical company focused on genetically defined diseases, has entered into an exclusive worldwide license agreement with Oscotec Inc to develop and commercialize, Cevidoplenib, a n... Full story

Yahoo Finance • last month

Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor Cevidoplenib

Agios obtains exclusive global rights to novel, late-stage, next-generation, oral SYK inhibitor Agreement diversifies Agios’ rare hematology portfolio with expansion into immune thrombocytopenia, unlocking up to $1 billion in peak U.S. sal... Full story

Yahoo Finance • 2 months ago

Agios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic Syndromes

Results did not meet predefined threshold to support further development in LR-MDS Tebapivat was well tolerated, with no new safety signals observed CAMBRIDGE, Mass., May 29, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:... Full story

Yahoo Finance • 2 months ago

Agios’ PYRUKYND® (mitapivat) Approved in the European Union for Adults with Thalassemia

PYRUKYND is the only medicine approved in the EU for adults with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassemia Mitapivat is now approved for thalassemia in the U.S., Saudi Arabia, United Arab Emirates, and... Full story

Yahoo Finance • 2 months ago

Here's Why Shares in Agios Pharmaceuticals Soared This Week (And What to Expect Next in 2026)

Shares in Agios Pharmaceuticals(NASDAQ: AGIO) rose by 11.2% this week, putting the stock into positive territory for the year. The move comes after a well-received first-quarter earnings report that showed strong progress in Aqvesme's U.S.... Full story

Yahoo Finance • 3 months ago

BofA Reaffirms Buy Rating for Agios Pharmaceuticals (AGIO)

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) is one of the 10 oversold small cap stocks to buy now. On April 21, BofA analyst Alec Stranahan reduced the price target on Agios Pharmaceuticals Inc. (NASDAQ:AGIO) to $41 from $44, while maintaini... Full story

Yahoo Finance • 3 months ago

Here's Why Agios Pharmaceuticals Stock Slumped This Week (And What Investors Have to Look Forward to in 2026)

Key Points Agios' price target was lowered due to increased regulatory risk. Novo Nordisk's etavopivat outperformed Agios' mitapivat in Phase 3 trials. Agios has a potential pipeline catalyst in 2026 with tebapivat.10 stocks we like bette... Full story

Yahoo Finance • 3 months ago

Agios (AGIO) Q2 2025 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, July 31, 2025 at 8 a.m. ET CALL PARTICIPANTS Chief Executive Officer — Brian M. GoffChief Financial Officer — Cecilia JonesChief Commercial Officer — Tsveta MilanovaChief Medical Officer —... Full story

Yahoo Finance • 3 months ago

Why Novo Nordisk's Surprise Win Hammered Agios Pharmaceuticals Stock

Shares of Agios Pharmaceuticals took a header Monday after Novo Nordisk's rival sickle cell treatment succeeded in Phase 3 testing. Continue Reading... Full story

Yahoo Finance • 3 months ago

Agios Pharmaceuticals stock tumbles 25% after Novo data

Investing.com -- Agios Pharmaceuticals Inc. (NASDAQ:AGIO) shares fell 25% Monday after rival Novo Nordisk released positive data for its experimental sickle cell disease therapy. Novo Nordisk said etavopivat demonstrated a 27% reduction i... Full story

Yahoo Finance • 3 months ago

Agios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ET

Agios Pharmaceuticals, Inc. CAMBRIDGE, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare di... Full story

Yahoo Finance • 3 months ago

Why Agios Pharmaceuticals Stock Is Up More Than 21% Today

Drugmaker Agios Pharmaceuticals(NASDAQ: AGIO) is positioning to win the FDA's approval of its mitapivat as a treatment for sickle cell disease sooner than investors may have been expecting. That's the overarching takeaway from this mornin... Full story

Yahoo Finance • 3 months ago

Insider Sells AGIO Shares Worth $82,000 -- But Context Is Everything

Viswanadhan Krishnan, Chief Corporate Development and Strategy Officer at Agios Pharmaceuticals(NASDAQ:AGIO), reported the open-market sale of 2,959 shares of common stock for a total of roughly $82,000 on March 5, 2026, according to an SE... Full story

Yahoo Finance • 4 months ago

How The Agios Pharmaceuticals (AGIO) Story Is Shifting After Aqvesme Approval And New Targets

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. The updated fair value estimate for Agios Pharmaceuticals has shifted to US$38.88 from US$36.75, while several bullish... Full story

Yahoo Finance • 5 months ago

Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

PYRUKYND® (mitapivat) worldwide net revenues of $20.0 million in fourth quarter and $54.0 million for full year AQVESME™ (mitapivat) for thalassemia now available in U.S. following FDA approval Company will have pre-sNDA meeting with FDA f... Full story

Yahoo Finance • 7 months ago

UiPath, Ramaco Resources And 3 Stocks To Watch Heading Into Wednesday

With U.S. stock futures trading slightly lower this morning on Wednesday, some of the stocks that may grab investor focus today are as follows: UiPath Inc.(NYSE:PATH) shares gained in extended trading on Tuesday after it was announced tha... Full story

Yahoo Finance • 7 months ago

Here's Why Shares in Agios Pharmaceuticals Popped Today

Key Points The new indication is relatively rare in the U.S., but pricing is substantial, and the need for the treatment is significant. The positive update turns the company's fortunes around after a disappointing update earlier in the y... Full story